Inspire Medical Systems, Inc. (INSP)
Inspire Medical Systems, Inc. (INSP) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inspire Medical Systems, Inc. (INSP) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inspire Medical: Buy Or Sell INSP Stock After Its 30% Rally?
Inspire Medical Systems' stock recently saw a significant surge, reacting to news that appears to be important. But does the increase from yesterday indicate that this is a good time to buy, or are we merely trying to catch a falling knife?
Inspire Medical Stock Is Down 41% This Year. Why It's Surging Today.
The maker of an implant to treat sleep apnea receives an upgrade to Buy from Hold at Stifel.
Inspire Medical Systems, Inc. (INSP) Presents at UBS Global Healthcare Conference 2025 Transcript
Inspire Medical Systems, Inc. ( INSP ) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST Company Participants Timothy Herbert - Founder, Chairman, CEO & President Ezgi Yagci - Vice President of Investor Relations Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good morning, everyone.
INSP Stock Gains Following Q3 Earnings Beat, Gross Margin Expands
Inspire Medical tops third-quarter 2025 estimates as revenue climbs and gross margin improves, with full-year EPS guidance raised.
Baron Discovery Fund Q3 2025 Contributors And Detractors
Baron Discovery Fund ended the quarter up 2.85% but underperformed its benchmark, the Russell 2000 Growth Index. Leading defense technology provider Kratos Defense & Security Solutions contributed to performance following a strong earnings report and continued momentum across its business segments. PAR Technology's shares fell during the quarter after the company lowered its full-year growth outlook to 15% from 20%.
Inspire Medical Systems, Inc. (INSP) Q3 2025 Earnings Call Transcript
Inspire Medical Systems, Inc. ( INSP ) Q3 2025 Earnings Call November 3, 2025 5:00 PM EST Company Participants Ezgi Yagci - Vice President of Investor Relations Timothy Herbert - Founder, Chairman, CEO & President Richard Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - BofA Securities, Research Division Adam Maeder - Piper Sandler & Co., Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Danielle Antalffy - UBS Investment Bank, Research Division David Rescott - Robert W. Baird & Co. Incorporated, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Shagun Singh Chadha - RBC Capital Markets, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Michael Sarcone - Jefferies LLC, Research Division Christopher Pasquale - Nephron Research LLC Richard Newitter - Truist Securities, Inc., Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Michael Polark - Wolfe Research, LLC Michael Kratky - Leerink Partners LLC, Research Division Presentation Operator Good afternoon.
Inspire Medical Systems (INSP) Tops Q3 Earnings and Revenue Estimates
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $0.15 per share. This compares to earnings of $0.6 per share a year ago.
INSP Shares Down Despite Strong Clinical Data From Inspire V Trials
Inspire Medical's Inspire V system shows strong safety, faster surgeries, and higher patient adherence in new trials.
Why Is Inspire (INSP) Up 7.5% Since Last Earnings Report?
Inspire (INSP) reported earnings 30 days ago. What's next for the stock?
Inspire Medical: Hiccups For The Sleep Business
Inspire Medical Systems faced a major setback after delays in the Inspire V launch, leading to slashed guidance and a sharp share price drop. Despite near-term volatility and margin pressure, the company's valuation now appears attractive at less than 3x sales, supported by a strong balance sheet. Management expects revenue growth to reaccelerate in 2026, offering comfort to long-term investors despite current uncertainty around margins.
Is the Options Market Predicting a Spike in Inspire Medical Systems Stock?
Investors need to pay close attention to INSP stock based on the movements in the options market lately.
